3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOWill not start
We expect faster clearance of psoriatic lesions with the use of short-contact, local tar application during UVB-therapy, which will result in a lower cumulative UVB dosage.
Approved WMORecruiting
To determine if EBUS / EUS-B guided nodal/lung tumor sampling with 22 Gauge (G) TBNB (Acquire**) needles results in improved tissue core sample acquisition in comparison to standard 22 G TBNA needles for the diagnosis and staging of lung cancer.